[
  {
    "ts": "2026-01-23T14:15:00+00:00",
    "headline": "Philip Morris International Urges FDA Advisory Committee to Recommend Authorizing ZYN as a Modified Risk Tobacco Product",
    "summary": "STAMFORD, CT, January 23, 2026--Experts from Philip Morris International (PMI) (NYSE: PM) yesterday presented scientific evidence to the U.S. Food and Drug Administration’s (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) as part of the FDA’s process for a Modified Risk Tobacco Product (MRTP) designation for their ZYN nicotine pouch products. This designation would allow PMI’s U.S. family of businesses to communicate to U.S. legal-aged, 21+ adult cigarette smokers that switching comp",
    "url": "https://finance.yahoo.com/news/philip-morris-international-urges-fda-141500771.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "3dc8251d-10db-3646-a277-d25e844223a4",
      "content": {
        "id": "3dc8251d-10db-3646-a277-d25e844223a4",
        "contentType": "STORY",
        "title": "Philip Morris International Urges FDA Advisory Committee to Recommend Authorizing ZYN as a Modified Risk Tobacco Product",
        "description": "",
        "summary": "STAMFORD, CT, January 23, 2026--Experts from Philip Morris International (PMI) (NYSE: PM) yesterday presented scientific evidence to the U.S. Food and Drug Administration’s (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) as part of the FDA’s process for a Modified Risk Tobacco Product (MRTP) designation for their ZYN nicotine pouch products. This designation would allow PMI’s U.S. family of businesses to communicate to U.S. legal-aged, 21+ adult cigarette smokers that switching comp",
        "pubDate": "2026-01-23T14:15:00Z",
        "displayTime": "2026-01-23T14:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/40ccd18f963eba0e06a73017bfbdce7c",
          "originalWidth": 3543,
          "originalHeight": 612,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_tlTeqdMAo9ELsr.MDUjiQ--~B/aD02MTI7dz0zNTQzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/40ccd18f963eba0e06a73017bfbdce7c.cf.webp",
              "width": 3543,
              "height": 612,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1R0Ed9DyZX3jwushu_EN9Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/40ccd18f963eba0e06a73017bfbdce7c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/philip-morris-international-urges-fda-141500771.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/philip-morris-international-urges-fda-141500771.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]